Email this article 
Hide
Show all
Original Research
Overview of HIV-related lipodystrophy
Southern African Journal of HIV Medicine | Vol 14, No 1 | a100 |
DOI: https://doi.org/10.4102/sajhivmed.v14i1.100
| © 2013 T Marie Rossouw, M E Botes, F Conradie
| This work is licensed under CC Attribution 4.0
Submitted: 12 December 2013 | Published: 26 February 2013
Submitted: 12 December 2013 | Published: 26 February 2013
About the author(s)
T Marie Rossouw, Department of Family Medicine, Faculty of Health Sciences, University of Pretoria, South AfricaM E Botes, Private practice, Pretoria, South Africa
F Conradie, Department of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Abstract
Lipodystrophy is a well-recognised adverse effect of HIV and antiretroviral therapy, with certain antiretrovirals, specifically thymidine analogues, implicated in the aetiology and pathogenesis. Lipodystrophy is often accompanied by metabolic complications, such as hyperlipidaemia and insulin resistance, which increase risk for cardiovascular disease. There are limited data on the effect of treatment modification, pharmacological interventions and surgical management on this condition.
Here we summarise the latest data on lipodystrophy, with the aim of facilitating informed decision-making in managing this condition. In light of the absence of cost-effective measures to treat lipoatrophy and lipohypertrophy, prevention remains the best option; we recommend targeted annual screening. Healthcare workers should be sensitised to early detection in patients on thymidine-based regimens, and affected patients should be switched to an appropriate regimen as soon as feasible. There is no evidence to support the use of new-generation ARVs, except in patients with significant hypercholesterolaemia, where atazanavir and raltegravir may present better options.
S Afr J HIV Med 2013;14(1):29-33. DOI:10.7196/SAJHIVMED.871
Here we summarise the latest data on lipodystrophy, with the aim of facilitating informed decision-making in managing this condition. In light of the absence of cost-effective measures to treat lipoatrophy and lipohypertrophy, prevention remains the best option; we recommend targeted annual screening. Healthcare workers should be sensitised to early detection in patients on thymidine-based regimens, and affected patients should be switched to an appropriate regimen as soon as feasible. There is no evidence to support the use of new-generation ARVs, except in patients with significant hypercholesterolaemia, where atazanavir and raltegravir may present better options.
S Afr J HIV Med 2013;14(1):29-33. DOI:10.7196/SAJHIVMED.871
Keywords
HIV; Lipodystrophy; Metabolic complications
Metrics
Total abstract views: 4021Total article views: 10165